Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at five years after completing treatment.
This article was originally published on MedicalXpress.com